Iris Pharma

Iris Pharma company information, Employees & Contact Information

Explore related pages

Related company profiles:

Not just an ophthalmology-focused CRO, Iris Pharma helps clients around the world navigate every stage of the drug and device development process and delivers customized solutions for: • Assessing possible therapeutic effect in ocular diseases • Adding value to promising drug candidates or medical devices • Designing development plans and preclinical packages and carrying out studies to proceed with confidence from bench to bedside • Providing the comprehensive clinical development services you need, from First-in-Human through Phase IV and Post-marketing follow-through We accompany start-up companies, biotechnology companies, large pharmaceutical companies, pharmaceutical labs, universities, research organizations and consultants in their ophthalmology projects. Our assets: • 32 years of experience in the field of ophthalmology research • All ophthalmic indications mastered • 70+ FDA, PMDA & EMA new ocular drug approvals and ophthalmic medical device marketing authorizations • State-of-the-art medical and scientific equipment • Highly specialized and qualified staff • Statement of compliance with GLP and GCLP • Adherence to all trial-related requirements (ICH-GCP) • French research tax credit accreditation (CIR)

Company Details

Employees
64
Founded
-
Address
Allée Hector Pintus, La Gaude,06610,france
Phone
+33 4 93 59 49 59
Email
in****@****rma.com
Industry
Research Services
NAICS
Scientific Research and Development Services
Research and Development in the Physical, Engineering, and Life Sciences
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
HQ
La Gaude
Looking for a particular Iris Pharma employee's phone or email?

Iris Pharma Questions

News

ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 2nd Quarter 2025 - Business Wire

ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 2nd Quarter 2025 Business Wire

Innocan Pharma to Present at the 2025 ThinkEquity Conference - The Malaysian Reserve

Innocan Pharma to Present at the 2025 ThinkEquity Conference The Malaysian Reserve

iQure Pharma Appoints Prof. Iris Loew-Friedrich, MD, as Clinical and R&D Advisor - citybiz

iQure Pharma Appoints Prof. Iris Loew-Friedrich, MD, as Clinical and R&D Advisor citybiz

Innocan Pharma Announces Closing of Private Placement - Yahoo Finance

Innocan Pharma Announces Closing of Private Placement Yahoo Finance

Lenz's Vizz wins FDA approval to crack 'large, untapped' market for presbyopia - Fierce Pharma

Lenz's Vizz wins FDA approval to crack 'large, untapped' market for presbyopia Fierce Pharma

Innocan Pharma Announces Promising Results of LPT-CBD Administered to Gottingen Minipigs, providing a good translational model and Provides Corporate Update - PR Newswire

Innocan Pharma Announces Promising Results of LPT-CBD Administered to Gottingen Minipigs, providing a good translational model and Provides Corporate Update PR Newswire

Liminatus Pharma Completes Merger with IRIS Acquisition - TipRanks

Liminatus Pharma Completes Merger with IRIS Acquisition TipRanks

ABIONYX Pharma Announces Its 2024 Full-Year Results - Business Wire

ABIONYX Pharma Announces Its 2024 Full-Year Results Business Wire

Innocan Pharma Reports Full Year 2024 Results with Revenues more than Doubling to US $29.4 million - PR Newswire

Innocan Pharma Reports Full Year 2024 Results with Revenues more than Doubling to US $29.4 million PR Newswire

French tech Keen Eye to bring its AI to Iris Pharma in partnership deal - Fierce Biotech

French tech Keen Eye to bring its AI to Iris Pharma in partnership deal Fierce Biotech

The many trends reshaping clinical trials: An interview with UCB’s Dr Iris Loew-Friedrich - pharmaphorum

The many trends reshaping clinical trials: An interview with UCB’s Dr Iris Loew-Friedrich pharmaphorum

Digitalisation of the clinical trial landscape - European Pharmaceutical Review

Digitalisation of the clinical trial landscape European Pharmaceutical Review

Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference - PR Newswire

Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference PR Newswire

Real Chemistry's new GLP-1 market analytics dashboard documents the rise of the 'GLP-1 influencer' - Fierce Pharma

Real Chemistry's new GLP-1 market analytics dashboard documents the rise of the 'GLP-1 influencer' Fierce Pharma

Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer - citybiz

Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer citybiz

ESMO: Bayer hopes to expand Nubeqa's prostate cancer reach with chemo-free regimen - Fierce Pharma

ESMO: Bayer hopes to expand Nubeqa's prostate cancer reach with chemo-free regimen Fierce Pharma

Innocan Pharma Announces First Half Of 2025 Financial Results - PR Newswire

Innocan Pharma Announces First Half Of 2025 Financial Results PR Newswire

Innocan Pharma Announces Public Filing of Registration Statement for Proposed U.S. Public Offering - PR Newswire

Innocan Pharma Announces Public Filing of Registration Statement for Proposed U.S. Public Offering PR Newswire

Italy opens antitrust case against Novartis, Roche and others, claiming collusion to delay biosim launch - Fierce Pharma

Italy opens antitrust case against Novartis, Roche and others, claiming collusion to delay biosim launch Fierce Pharma

Innocan Pharma First Granted Patent in Mexico for its Topical Pain Relief - PR Newswire

Innocan Pharma First Granted Patent in Mexico for its Topical Pain Relief PR Newswire

Liminatus Pharma enters SPAC merger deal with Iris Acquisition - Pharmaceutical Technology

Liminatus Pharma enters SPAC merger deal with Iris Acquisition Pharmaceutical Technology

Liminatus Pharma and Iris Acquisition Corp to Combine - citybiz

Liminatus Pharma and Iris Acquisition Corp to Combine citybiz

Innocan Pharma Partners With a Sanctuary For Injured Animals to Bring Remedy and Hope with its LPT-CBD injection - PR Newswire

Innocan Pharma Partners With a Sanctuary For Injured Animals to Bring Remedy and Hope with its LPT-CBD injection PR Newswire

Innocan Pharma's Poster on its Liposomal Synthetic CBD Technology Generates Interest at PAINWeek Conference - PR Newswire

Innocan Pharma's Poster on its Liposomal Synthetic CBD Technology Generates Interest at PAINWeek Conference PR Newswire

UCB's approval spree rolls on with FDA nod for Zilbrysq, its 2nd drug for myasthenia gravis - Fierce Pharma

UCB's approval spree rolls on with FDA nod for Zilbrysq, its 2nd drug for myasthenia gravis Fierce Pharma

Liposomal CBD Injection Technology (LPT-CBD) patent was allowed in Japan - PR Newswire

Liposomal CBD Injection Technology (LPT-CBD) patent was allowed in Japan PR Newswire

Genentech, ADA launch new 'eye pledge' to boost awareness of diabetes-related vision loss - Fierce Pharma

Genentech, ADA launch new 'eye pledge' to boost awareness of diabetes-related vision loss Fierce Pharma

Innocan Pharma Granted First Patent in India for its Liposomal CBD Injection - PR Newswire

Innocan Pharma Granted First Patent in India for its Liposomal CBD Injection PR Newswire

Iris Acquisition Corp confirms delisting and shareholder vote outcomes - Investing.com

Iris Acquisition Corp confirms delisting and shareholder vote outcomes Investing.com

FDA missing more approval target dates as COVID slows inspections - Fierce Pharma

FDA missing more approval target dates as COVID slows inspections Fierce Pharma

Roche's Susvimo has its advantages, but eye doctors are sticking with Eylea - Fierce Pharma

Roche's Susvimo has its advantages, but eye doctors are sticking with Eylea Fierce Pharma

Innocan Pharma to Participate in IR Labs' Investor Webinar on November 2, 2022 - Newsfile

Innocan Pharma to Participate in IR Labs' Investor Webinar on November 2, 2022 Newsfile

Innocan Pharma Announces First Quarter 2025 Financial Results with Continued Strong Revenue Growth and Provides Corporate Update - sharewise.com

Innocan Pharma Announces First Quarter 2025 Financial Results with Continued Strong Revenue Growth and Provides Corporate Update sharewise.com

Innocan Pharma’s CEO Iris Bincovich: 'We Are Already Expanding Post-COVID' - International Business Times

Innocan Pharma’s CEO Iris Bincovich: 'We Are Already Expanding Post-COVID' International Business Times

UCB buys rare disease drugmaker Zogenix for up to $1.9B, bolstering its epilepsy position - Fierce Pharma

UCB buys rare disease drugmaker Zogenix for up to $1.9B, bolstering its epilepsy position Fierce Pharma

J&J Vision debuts new try-it augmented reality tech application for Acuvue lenses in China - Fierce Pharma

J&J Vision debuts new try-it augmented reality tech application for Acuvue lenses in China Fierce Pharma

Transitioning Teva revamps branding to emphasize brand-generic unity - Fierce Pharma

Transitioning Teva revamps branding to emphasize brand-generic unity Fierce Pharma

Iris Inspection machines supports pharmaceutical glassmakers - Glass International

Iris Inspection machines supports pharmaceutical glassmakers Glass International

IRIS: Diabetes Drug Reduces Recurrent Stroke, MI in Patients With Insulin Resistance - Medscape

IRIS: Diabetes Drug Reduces Recurrent Stroke, MI in Patients With Insulin Resistance Medscape

Innocan Pharma's CBD-Loaded Liposome Platform Technology Demonstrates a Prolonged Release of CBD in Large Animals - FinancialContent

Innocan Pharma's CBD-Loaded Liposome Platform Technology Demonstrates a Prolonged Release of CBD in Large Animals FinancialContent

Top Iris Pharma Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant